These resources aid budget holders in making informed decisions and aid local planning on the introduction of key new medicines but are not formal NICE guidance. Each summary reviews efficacy, safety, user factors and resource implications.
The reviews this month are for:
- Nomegestrol/estradiol (Zoely®) - a new combined oral contraceptive
- Nalmefene (Selincro®) - a newly licensed treatment for alcohol dependence
Action: These summaries provide a good overview of the current evidence for these new medicines. This information will help to guide commissioning and prescribing decisions.